NTRK2 R458G

CI-VAR-00003855Explore in graph →CIViC 3144

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Atypical Chronic Myeloid Leukemia2
NTRK2 R458G	(oncogenic)	Oncogenic	C	Supports Oncogenicity	3	submitted	EID8610 This variant was found in one case of atypical CML out of 185 hematological malignancies. The authors propose that NTRK2 R458G, residing in the juxtamembrane domain, activates TrkB via noncanonical me… (full text at CIViC) PMID 32315394 · Joshi et al., 2020 · Open in CIViC	civic
NTRK2 R458G	Entrectinib + LarotrectinibSubstitutes	Predictive	C	Supports Sensitivity Response	2	submitted	EID8625 This variant was found in one case of atypical CML out of 185 hematological malignancies. The authors propose that NTRK2 R458G, residing in the juxtamembrane domain, activates TrkB via noncanonical me… (full text at CIViC) PMID 32315394 · Joshi et al., 2020 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Chronic Myeloid Leukemia, BCR-ABL1 Positive1
NTRK2 R458G	Crizotinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID8609 The authors propose that NTRK2 R458G, residing in the juxtamembrane domain, activates TrkB via noncanonical mechanisms that may involve altered interactions between the mutant receptor and lipids in t… (full text at CIViC) PMID 32315394 · Joshi et al., 2020 · Open in CIViC	civic